The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Neuren Pharmaceuticals (NEU) opens its Phase Two clinical trial of its NNZ-2591 drug in Angelman syndrome (AS) for enrollment
  • The trial is being conducted at three hospitals in Brisbane, Melbourne and Sydney under an investigational new drug application with the US Food and Drug Administration
  • Neuren says the trial will aim to examine the safety, tolerability, pharmacokinetics and efficacy of NNZ-2591 over 13 weeks of treatment
  • In parallel with the Phase Two trial, Neuren is also executing the foundational work to prepare for Phase Three development across multiple indications
  • Shares in Neuren are trading grey at $3.95 per share at 12:22 pm AEST

Neuren Pharmaceuticals (NEU) has opened its Phase Two clinical trial of its NNZ-2591 drug in Angelman syndrome (AS) for enrollment.

The first subjects are expected to enter the trial “imminently” at the Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children’s Health Queensland Hospital.

The trial is being conducted at three hospitals in Brisbane, Melbourne and Sydney under an investigational new drug application with the US Food and Drug Administration.

Neuren said the aim of the trial was to examine the safety, tolerability, pharmacokinetics and efficacy of NNZ-2591 over 13 weeks of treatment under which all subjects will receive an oral liquid dose twice daily.

CEO Jon Pilcher said Angelman syndrome was a “seriously debilitating” condition with no approved medicines.

“In the ube3a knockout mouse model of Angelman, treatment with NNZ-2591 normalized all the deficits, so we are now eager to observe the effects of treatment in children,” Mr Pilcher said.

In parallel with the Phase Two trial, Neuren is also executing the foundational work to prepare for Phase Three development across multiple indications.

Angelman syndrome is characterized by severe developmental delay and learning disabilities that become noticeable by the age of six to 12 months.

Shares in Neuren were trading grey at $3.95 per share at 12:22 pm AEST.

NEU by the numbers
More From The Market Online

Week 13 Wrap: Easter bunny delivers new all time high for ASX200

Another week, another all time high. The ASX200 clocked 7,901pts on Thursday for the first time…
The Market Online Video

Market Close: Green lights up on ASX for Easter hunt go

The ASX200 closed the day in record territory - nearly a per cent up with every…

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Market Update: ASX glows red hot with another hit record

The ASX200 is trading up, hitting a new high of 7901 point and eclipsing the last…